489 related articles for article (PubMed ID: 27163986)
21. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
[TBL] [Abstract][Full Text] [Related]
22. Bosentan for digital ulcers in patients with systemic sclerosis.
Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
[TBL] [Abstract][Full Text] [Related]
23. A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol.
van Rhijn-Brouwer FCC; Gremmels H; Fledderus JO; Schuurman AH; Bonte-Mineur F; Vonk MC; Voskuyl AE; de Vries-Bouwstra JK; Coert JH; Radstake TRDJ; van Laar JM; Verhaar MC;
BMJ Open; 2018 Aug; 8(8):e020479. PubMed ID: 30127049
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.
Hachulla E; Hatron PY; Carpentier P; Agard C; Chatelus E; Jego P; Mouthon L; Queyrel V; Fauchais AL; Michon-Pasturel U; Jaussaud R; Mathian A; Granel B; Diot E; Farge-Bancel D; Mekinian A; Avouac J; Desmurs-Clavel H; Clerson P;
Ann Rheum Dis; 2016 Jun; 75(6):1009-15. PubMed ID: 25995322
[TBL] [Abstract][Full Text] [Related]
25. Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan.
Zelenietz C; Pope J
Ann Rheum Dis; 2010 Nov; 69(11):2055-6. PubMed ID: 20959328
[No Abstract] [Full Text] [Related]
26. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
Sidharta PN; van Giersbergen PL; Dingemanse J
J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
[TBL] [Abstract][Full Text] [Related]
28. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
Correa MJ; Mariz HA; Andrade LE; Kayser C
Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.
Tillon J; Hervé F; Chevallier D; Muir JF; Levesque H; Marie I
Br J Dermatol; 2006 May; 154(5):1000-2. PubMed ID: 16634913
[No Abstract] [Full Text] [Related]
30. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study.
Roman Ivorra JA; Simeon CP; Alegre Sancho JJ; Egurbide MV; Castillo MJ; Lloria X; Fonollosa V
J Rheumatol; 2011 Aug; 38(8):1631-5. PubMed ID: 21632679
[TBL] [Abstract][Full Text] [Related]
31. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.
Tsifetaki N; Botzoris V; Alamanos Y; Argyriou E; Zioga A; Drosos AA
J Rheumatol; 2009 Jul; 36(7):1550-2. PubMed ID: 19567637
[No Abstract] [Full Text] [Related]
32. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
33. [Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].
Riemekasten G; Beissert S; Distler JH; Kreuter A; Müller-Ladner U
Z Rheumatol; 2017 Apr; 76(3):228-237. PubMed ID: 27535277
[TBL] [Abstract][Full Text] [Related]
34. Macitentan: A Review in Pulmonary Arterial Hypertension.
Keating GM
Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
[TBL] [Abstract][Full Text] [Related]
35. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
García de la Peña-Lefebvre P; Rodríguez Rubio S; Valero Expósito M; Carmona L; Gámir Gámir ML; Beltrán Gutiérrez J; Díaz-Miguel C; Orte Martínez J; Zea Mendoza AC
Rheumatology (Oxford); 2008 Apr; 47(4):464-6. PubMed ID: 18263597
[TBL] [Abstract][Full Text] [Related]
36. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA; Simonneau G; D'Armini AM; Fedullo P; Howard LS; Jaïs X; Jenkins DP; Jing ZC; Madani MM; Martin N; Mayer E; Papadakis K; Richard D; Kim NH;
Lancet Respir Med; 2017 Oct; 5(10):785-794. PubMed ID: 28919201
[TBL] [Abstract][Full Text] [Related]
37. [Digital ulcers in systemic sclerosis: use of endotheline antagonists].
Mota J; Castellano A; Santiago F; Carvalho P; Madeira AS; Pereira De Moura JM; Nascimento Costa JM
Acta Med Port; 2011; 24(5):837-42. PubMed ID: 22525638
[TBL] [Abstract][Full Text] [Related]
38. [Digital ulcers in systemic sclerosis].
Guillevin L
Presse Med; 2008 Apr; 37(4 Pt 2):735-6. PubMed ID: 18258409
[No Abstract] [Full Text] [Related]
39. Macitentan for the treatment of pulmonary arterial hypertension.
Hong IS; Coe HV; Catanzaro LM
Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
[TBL] [Abstract][Full Text] [Related]
40. Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists.
Ngcozana T; Ong V; Denton CP
BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24682137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
